Ascendis Pharma Oncology Division A/S
- Adresse
- Tuborg Boulevard 12
2900 Hellerup - Hjemmeside
- www.ascendispharma.com
- Telefon
- 70 22 22 44
Note 2 - Main ActivityAscendis Pharma Oncology Division A/S is a wholly owned subsidiary in the Ascendis Pharma Group,which is a global biopharmaceutical group focused on applying its innovative TransCon technologyplatform to make a meaningful difference for patients.The Ascendis Pharma Group has developed a portfolio of product candidates by utilizing its TransContechnologies with clinically validated parent drugs. The primary focus of Ascendis Pharma OncologyDivision A/S is activities directed towards development of improved products within oncology.
Regnskabsår 01.01.2025 – 31.12.2025 · beløb i EUR.
Regnskab (t.eur)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Resultatopgørelse | |||||
| Bruttofortjeneste | -85.226 | -92.475 | -140.146 | -62.367 | -46.677 |
| Resultat af primær drift | -85.274 | -92.552 | -140.193 | -62.459 | -46.763 |
| Finansielle indtægter | 142 | 713 | 697 | 36 | 35 |
| Finansielle omkostninger | 35.882 | 14.926 | 4.842 | 2.570 | 1.356 |
| Resultat før skat | -121.014 | -106.765 | -144.339 | -64.992 | -48.084 |
| Skat af årets resultat | -10.883 | -390 | -229 | -80 | -104 |
| Årets resultat | -110.131 | -106.375 | -144.110 | -64.912 | -47.980 |
| Balance | |||||
| Anlægsaktiver | – | – | – | 0 | 2.633 |
| Omsætningsaktiver | 0 | 99 | 457 | 5.604 | 2.976 |
| Likvide beholdninger | 0 | 99 | 442 | 479 | 450 |
| Aktiver i alt | 0 | 99 | 457 | 5.604 | 5.608 |
| Selskabskapital | 120 | 120 | 120 | 120 | 120 |
| Overført resultat | -501.757 | -391.626 | -285.252 | -141.141 | -76.229 |
| Egenkapital | -501.637 | -391.506 | -285.131 | -141.021 | -76.109 |
| Langfristet gæld | 487.416 | 391.591 | 285.576 | 146.609 | 81.709 |
| Kortfristet gæld | 14.221 | 14 | 12 | 16 | 7 |
| Foreslået udbytte | – | – | -144.110 | – | – |
| Nøgletal | |||||
| Soliditetsgrad | – | -395.460,6 % | -62.440,8 % | -2.516,4 % | -1.357,1 % |
| Likviditetsgrad | 0 % | 707 % | 3.773 % | 35.244 % | 40.450 % |
| Antal ansatte | 0 | 0 | 0 | 0 | 0 |
Ledelse
- Michael Wolff JensenBestyrelsesformand
- Anni Lotte Kirstine PedersenBestyrelsesmedlem
- Jan Møller MikkelsenBestyrelsesmedlem
- Jan Møller MikkelsenDirektion · Chief Executive Officer
Ifølge underskrifterne i årsrapporterne. Personer identificeres ud fra navn.
Revision
- Deloitte Statsautoriseret RevisionspartnerselskabAuditor's report on audited financial statements · 2021–2025
Seneste erklæring: Auditor's report on audited financial statements